Pharmacological disruption of LY96–TLR4 interactions or inhibition of downstream NF-κB signaling has shown promise in preclinical studies [68,69,70], and could represent a therapeutic avenue to attenuate tumor-promoting inflammation while restoring anti-tumor immunity. This evidence concerns the gene NFKB1 and neoplasm.